# Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05631431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05631431](<https://clinicaltrials.gov/study/NCT05631431>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05631431

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 135 participants.

## Technical summary

Registry record NCT05631431. Randomized; triple masking; primary purpose supportive care. Start 2021-12-14 (actual); primary completion 2023-06-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose supportive care
- Phase: Phase 2
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT05631431, source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)
- Started: 2021-12-14 (actual) (ClinicalTrials.gov record NCT05631431, source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2023-06-29 (actual) (ClinicalTrials.gov record NCT05631431, source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)
- Completion: 2023-06-29 (actual) (ClinicalTrials.gov record NCT05631431, source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)
- Countries: Israel (ClinicalTrials.gov record NCT05631431, source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05631431-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus
- Condition: Type2 Diabetes
- Intervention (Dietary supplement): Curalin
- Lead sponsor: CuraLife
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 5aa3a71263065b0b2d297a347da9d7db8357e985805356858b4eacd8c20f73f3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
